We have located links that may give you full text access.
Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma.
Postȩpy Dermatologii i Alergologii 2018 October
Introduction: Asthma is a multiphenotypic disease, and therapeutic managenment in patients with severe asthma is particulary difficult, with conventional treatment of severe asthma showing poor efficacy.
Aim: To analyse forced expiratory volume in 1 s (FEV1 ) following the adminstration of omalizumab.
Material and methods: Six patinents (mean age: 50 ±12.6) with severe, uncontrolled asthma according to the GINA guidelines were enrolled in the study.
Results: Treatment with omalizumab increased in all subjects FEV1 by 17.28 ±13.4% after months and 18.57 ±13.4% after 12 months of treatment.
Conclusions: These results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma.
Aim: To analyse forced expiratory volume in 1 s (FEV1 ) following the adminstration of omalizumab.
Material and methods: Six patinents (mean age: 50 ±12.6) with severe, uncontrolled asthma according to the GINA guidelines were enrolled in the study.
Results: Treatment with omalizumab increased in all subjects FEV1 by 17.28 ±13.4% after months and 18.57 ±13.4% after 12 months of treatment.
Conclusions: These results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app